Pomalidomide plus low-dose dexamethasone in multiple myeloma with deletion 17p and/or translocation (4;14): IFM 2010-02 trial results. - Université de Rennes Accéder directement au contenu
Article Dans Une Revue Blood Année : 2015

Pomalidomide plus low-dose dexamethasone in multiple myeloma with deletion 17p and/or translocation (4;14): IFM 2010-02 trial results.

Xavier Leleu
  • Fonction : Auteur
Margaret Macro
  • Fonction : Auteur
Cyrille Hulin
  • Fonction : Auteur
Laurent Garderet
Brigitte Pegourie
  • Fonction : Auteur
Brigitte Kolb
  • Fonction : Auteur
Anne Marie Stoppa
  • Fonction : Auteur
Sabine Brechiniac
  • Fonction : Auteur
Beatrice Thielemans
  • Fonction : Auteur
Brigitte Onraed
  • Fonction : Auteur
Anne Banos
  • Fonction : Auteur
Laurence Lacotte
  • Fonction : Auteur
Mourad Tiab
  • Fonction : Auteur
Mamoun Dib
  • Fonction : Auteur
Jean-Gabriel Fuzibet
  • Fonction : Auteur
Marie Odile Petillon
  • Fonction : Auteur
Philippe Rodon
  • Fonction : Auteur
Marc Wetterwald
  • Fonction : Auteur
Lotfi Benboubker
  • Fonction : Auteur
Denis Caillot
  • Fonction : Auteur
Jean Paul Fermand
  • Fonction : Auteur
Philippe Moreau
Herve Avet-Loiseau

Résumé

The combination of pomalidomide and low-dose dexamethasone (Pom-Dex) can be safely administered to patients with end-stage relapsed/refractory multiple myeloma (RRMM). However, we observed a shorter median progression-free survival (PFS) and overall survival (OS) in these patients when characterized with adverse cytogenetics (deletion 17p and translocation [4;14]) in the Intergroupe Francophone Myélome (IFM) 2009-02 trial. We then sought to determine whether MM with adverse cytogenetics would benefit more from Pom-Dex if exposed earlier in the multicenter IFM 2010-02 trial. The intention-to-treat population included 50 patients, with a median age of 63 years (38% were ≥65 years). Interestingly, there was a striking difference in time to progression (TTP), duration of response, and overall response rate (ORR) according to the presence of del(17p) compared with t(4;14) (TTP, 7.3 vs 2.8 months; duration of response, 8.3 vs 2.4 months; and ORR, 32% vs 15%). OS was prolonged after Pom-Dex, particularly in t(4;14), given the short TTP, suggesting that patients were rescued at relapse with further lines of therapy. Pom-Dex, a doublet immunomodulatory drug-based regimen, is active and well tolerated in adverse cytogenetic patients with early RRMM, particularly in those with del(17p), who are characterized by a high and rapid development of a refractoriness state and known for their poor prognosis. Future studies will determine the underlying mechanisms of Pom-Dex activity in del(17p). This trial is registered at www.clinicaltrials.gov as #NCT01745640.

Dates et versions

hal-01141134 , version 1 (10-04-2015)

Identifiants

Citer

Xavier Leleu, Lionel Karlin, Margaret Macro, Cyrille Hulin, Laurent Garderet, et al.. Pomalidomide plus low-dose dexamethasone in multiple myeloma with deletion 17p and/or translocation (4;14): IFM 2010-02 trial results.. Blood, 2015, 125 (9), pp.1411-7. ⟨10.1182/blood-2014-11-612069⟩. ⟨hal-01141134⟩
280 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More